Racura Oncology

16/09/2026

The evolving landscape of EGFR mutant lung cancer presents a $10 billion global market, with high prevalence among non-smokers.

In this Racura Symposium excerpt, Medical Oncologist Prof Nick Pavlakis from Royal North Shore Hospital and Racura Principal Scientist Dr Rodney Cusack discuss the competitive dynamics and our strategic approach to this clinical need.

🎥 Watch below

15/09/2026

A new feature in 'In Vivo' discusses the growing potential of drug repurposing, highlighting companies like Racura who have revitalised compounds previously shelved by pharmaceutical companies.

At Racura, we are actively pursuing opportunities that others have missed. As Racura CEO Dr Daniel Tillett says in the piece: “I often go back and read the old literature and find an amazing drug, then ask why it never reached the market.”

Racura is developing RC220, a novel formulation of bisantrene, originally developed in the 1970s. RC220 has been reformulated to improve patient administration, and is being investigated across a number of indications for its ability to target the MYC protein - a key driver implicated in a range of cancers.

Read the full feature here: https://insights.citeline.com/in-vivo/innovation/graveyard-drug-hunters-how-racura-and-cereno-are-repurposing-drugs-that-pharma-threw-away-QIP6QEHZKRDLTHBMSWPVVJE7QA/

A contrarian cohort of drug companies is betting that pharma's most undervalued assets are the ones it already threw away.

14/09/2026

In the next instalment of our key highlights series from the Racura Symposium, Dr Anupa Kudva reviews the historical clinical success of our lead asset, (E,E)-Bisantrene, which received initial approval in France during the 1980s for acute myeloid leukaemia (AML), under a different formulation.

Dr Anupa details the 40 years of positive clinical results associated with (E,E)-Bisantrene, which bolsters our proprietary drug RC220.

🎥 Watch segment

10/09/2026

Continuing our series of key highlights from the Racura Symposium, Chairman Dr Peter Smith outlines our clinical portfolio and the distinct risk profiles of our three ongoing trials.

He notes that our programme targeting acute myeloid leukaemia (AML) - a known MYC-driven cancer where our drug has demonstrated efficacy - is advancing to Phase 3. He also outlines how our HARNESS-1 and CPACS clinical studies ask two different questions, specifically investigating the drug's capacity to overcome treatment resistance in non-small cell lung cancer, and the extent to which it can protect heart muscle cells from chemotherapy-induced damage.

🎥 Watch now

09/09/2026

Racura Oncology (ASX: RAC) has been selected to present new preclinical data on its lead asset, RC220, at the 2026 Frontiers in Cancer Science (FCS) Conference, held in partnership with the American Association for Cancer Research (AACR), in Singapore this November.

The research establishes that (E,E)-bisantrene is the active isomer responsible for stabilising the G-quadruplex region within the MYC gene promoter region, leading to reduced MYC gene expression.

Importantly, the findings provide further mechanistic support for Racura’s clinical programs across acute myeloid leukaemia, EGFR-mutant non-small cell lung cancer and anthracycline cardioprotection.

Read the full announcement here: https://shorturl.at/mTRr6

07/09/2026

We’re pleased to invite interested investors to an in-person morning tea in Adelaide on Wednesday, 30 September 2026.

Hosted by Racura CEO, Dr Daniel Tillett, this is a great opportunity for investors to hear the latest updates on Racura's clinical programs, and ask questions.

Briefing Details:
🗓️ Date: Wednesday, 30 September 2026
⏰ Time: 10:15 AM for a 10:30 AM start
📍 Location: Adina Adelaide Treasury (Vault 2 room), 2 Flinders St, Adelaide, SA
📩 RSVP: Places are limited.

Please RSVP to [email protected] by Monday, 21 September 2026.

Read the full announcement here:https://rac.live.irmau.com/pdf/0a02f279-7428-4f02-b62b-6f535174764f/Platform/ListPage/Racura-Oncology-Adelaide-Investor-Briefing.pdf

07/09/2026

While targeted therapies have revolutionised oncology, acquired resistance remains a significant challenge for many patients. In the next snippet from our Investor Symposium , VP of Research Prof Mike Kelso examines how the MYC protein, found in many major cancer indications, drives this resistance and how Racura’s preclinical studies looking into novel treatments demonstrate broad synergy with targeted agents across multiple cancer types.

🎥 View the clip

03/09/2026

Racura Oncology CEO Dr. Daniel Tillett took the stage at the recent TechKnow Invest Roadshow, to share our approach to drug development and outline the potential of RC220.

Racura Oncology is rapidly advancing three clinical programs focused on MYC, a historically "undruggable” oncology target dysregulated in up to 70% of cancers.

The TechKnow presentation is now available to view - find the link here: https://announcements.racuraoncology.com/activity-updates/yOZDdP-racura-oncology-at-techknow-invest-roadshow-july-2026

Watch Racura Oncology's CEO, Dr Daniel Tillett present at TechKnow Invest Road Day 2 July 2026.

02/09/2026

The MYC protein has long been considered the 'holy grail' of oncology targets, yet remains notoriously difficult to silence. In this Racura Symposium highlight, VP of Research Prof Mike Kelso outlines our novel therapeutic approach to targeting MYC-driven cancers by binding to and stabilising three-dimensional DNA structures known as G-quadruplexes.

🎥 Learn more in the video

01/09/2026

Racura Oncology (ASX: RAC) is pleased to announce an important milestone for our CPACS Phase 1 trial, with Ewha Womans University Seoul Hospital becoming the first Korean site to open for patient enrolment.

The CPACS trial is evaluating RC220 in combination with doxorubicin in patients with advanced solid tumours, with the aim of investigating both cardioprotection and potential anticancer synergy.

Additional Korean sites, including Severance Hospital and Samsung Medical Center, are scheduled to be activated and opened for patient enrolment in the coming weeks.

The activation of these sites marks an important step forward for the CPACS trial, and is expected to accelerate patient recruitment and trial progress.

We thank our investigators and clinical teams in Korea as we advance RC220 through clinical development.

Read the full announcement here:https://announcements.racuraoncology.com/announcements/7710953